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Summary
Objective: To investigate the potential synergistic and differential effects of cytokine combinations on proteoglycan aggregate catabolism in
cartilage.
Methods: Bovine articular cartilage explants were maintained in organ culture and subjected to stimulation with cytokine combinations includ-
ing interleukin-1a (IL-1a), IL-1b, IL-6, IL-17, tumor necrosis factor-a (TNFa) and oncostatin M (OSM). Aggrecan, link protein and hyaluronan
(HA) release and degradation were analyzed, and the effect of the hyaluronidase inhibitor apigenin was investigated.
Results: For all cytokine mixtures studied cleavage of aggrecan only by aggrecanase action was apparent. However, OSM acting synergis-
tically with IL-1 or TNFa produced a rapid release of all proteoglycan aggregate components due to both aggrecan and HA degradation. This
was abolished by the hyaluronidase inhibitor, apigenin. In addition, in the presence of OSM a low molecular weight aggrecan G3 product was
observed, suggesting altered aggrecanase cleavage activity is induced by this cytokine.
Conclusions: Under cytokine stimulation, aggrecan release from cartilage may take place via proteolysis of the aggrecan core protein or via
depolymerization of HA, with the latter mechanism being induced by OSM. OSM is associated with joint inﬂammation and its participation may
account for the more rapid loss of aggrecan from articular cartilage in the inﬂammatory arthritides, compared to osteoarthritis.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Cartilage forms the bearing surfaces of diarthrodial joints and
is responsible for their smooth articulation. This tissue con-
sists of a mostly type II collagen network which entraps pro-
teoglycan aggregates made up of multiple molecules of the
large aggregating proteoglycan, aggrecan, non-covalently
attached to a central hyaluronan (HA) ﬁlament. Each of these
interactions is stabilized by a small glycoprotein termed link
protein (LP), rendering thewhole complex stable to extremes
of pressure and pH.
Aggrecan is a multidomain proteoglycan. Its 250 kDa core
protein consists of a series of domains eachwith different func-
tions. TheN-terminal 50 kDaglobular domain, termedG1, con-
sists of an immunoglobulin-like motif responsible for protein/
protein interactions between LP and aggrecan and two copies
of a motif originally found in LP, which is responsible for HA
binding. G1 is connected to a second globular domain (G2)
through an approximately 140 residue extended region termed
as the interglobular domain (IGD). G2 consists of two copies of
the LP motif, however in vitro studies have failed to show HA
binding to isolated G2 domains1. Attached to the G2 domain
is an extended region (keratan sulfate (KS) domain) which is
richly substituted with KS2. This is followed by the chondroitin
sulfate 1 (CS1) domainwhere a large amount of the glycosami-
noglycan (GAG) content (CS chains) is located3. The CS1 is*Address correspondence and reprint requests to: Dr John S.
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98followed by a second region with CS substitution (CS2
domain). The C-terminus of the core protein consists of a third
globular domain (G3), containing an epidermal growth factor
(EGF)-likemotif followed by aC-type lectin-likemotif and a sushi
element. Evidence for carbohydratebindingof theG3domain
has been demonstrated4 and its presence is essential for
transport of the newly synthesized molecule from the cell5.
The large number ofCSandKSGAGchains on the aggrecan
molecule give the complex its immense negative charge,
which is essential for cartilage function.
In general aggrecan is a universal substrate for prote-
ases6,7 but is cleaved at speciﬁc sites along the core protein
by particular activities present in the joint. In recent years, it
has become clear that matrix metalloproteinases (MMPs),
such as stromelysin (MMP-3) and collagenase 3 (MMP-
13), as well as the members of the ADAMTS (a disintegrin
and metalloproteinase with thrombospondin motifs) namely
ADAMTS-4, ADAMTS-5 and possibly ADAMTS-1, -8, -9
and -15, also termed aggrecanases, are responsible for ag-
grecan degradation8 and cleavage sites on the molecule
have been identiﬁed. In particular, aggrecan cleavage in
the IGD region produces different sized G1 fragments de-
pending on whether they are MMP or aggrecanase gener-
ated9. In addition, the aggrecanases are known to cleave
the aggrecan core protein at four speciﬁc sites in the CS2 re-
gion giving rise to a series of G3-containing fragments whose
size can be diagnostic for the action of this enzyme10. While
such proteolysis is commonly associated with aggrecan deg-
radation in pathological states, similar proteolytic processing
is also occurring during normal physiological turnover. The
level of protease involvement will determine whether aggre-
can degradation is destructive or non-destructive.
99Osteoarthritis and Cartilage Vol. 16, No. 1Loss of cartilage function is a major consequence of
arthritis pathology. Cartilage destruction due to the action
of metalloproteases is known to be stimulated by various cy-
tokines such as interleukin-1a (IL-1a), IL-b and tumor necro-
sis factor-a (TNFa) but the effect of several other cytokines
has also been invoked. The effect of these cytokines has
been shown to be enhanced by the presence of oncostatin
M (OSM)11, a cytokine normally associated with mononu-
clear cells and thought to play a role in the inﬂammatory
joint12. In this study, a series of proinﬂammatory cytokines
including OSM in combination with IL-1a, IL-b and TNFa
were used to investigate their ability to mediate early events
in aggrecan degradation. Interestingly, HA degradation was
seen to be amajor factor in the degradative potential induced
by OSM.MethodsCARTILAGE EXPLANT CULTUREBovine articular cartilage from metacarpophalangeal
joints of skeletally mature animals was obtained from a local
abattoir. Cartilage was dissected, cut into pieces of approx-
imately 5 mm3 and pre-cultured for 48 h in Dulbecco’s mod-
iﬁed Eagle’s medium buffered with 44 mM NaHCO3, 20 mM
4-(2-hydroxyethyl)piperazine-1-ethanesulfonate (HEPES) in
12-well culture plates at 100 mg tissue per 2 ml medium.
This was followed by a 6-day culture period where the
medium containing 0.1 mg bovine serum albumin (BSA)/ml
was supplemented with a variety of cytokines used either
alone or in combinations: human recombinant IL-1a (5 ng/
ml), IL-1b (5 ng/ml), TNFa (10 ng/ml), IL-6 (10 ng/ml), IL-17
(50 ng/ml) and OSM (10 ng/ml) (R&D). Preliminary experi-
ments or previous work have demonstrated that these con-
centrations of cytokine were optimal for the stimulation of
GAG release. The culture media were collected every 2
days and replaced by fresh media containing the different
combinations of cytokines. In some experiments, culture
was performed in the presence of the hyaluronidase inhibi-
tor, apigenin (100 mM, Calbiochem)13. The inhibitor was dis-
solved in dimethylsulfoxide (DMSO), and following dilution
DMSO was present at 1% in both inhibitor-treated and con-
trol cultures. All culture conditions were performed in tripli-
cate and where changes were evident experiments were
repeated at least twice to demonstrate reproducibility.GAG ASSAYThe sulfated GAG content of collected media was deter-
mined by the Dimethylmethylene Blue (DMMB) colorimetric
assay14. Samples (20 ml) were combined with 180 ml DMMB
reagent (46 mM DMMB, 40 mM glycine, and 40 mM NaCl,
pH 3.0) in a 96-well plate and absorbance at 530 nm was
measured. CS (Sigma) was used as a standard.PREPARATION OF TISSUE EXTRACTSTissue was extracted with 10 volumes (v/w) 4 M guanidi-
nium chloride/100 mM sodium acetate, pH 6.0, containing
protease inhibitors (1 mM phenylmethylsulfonyl ﬂuoride,
1 mM iodacetamide, 1 mM ethylenediaminetetraacetate
(EDTA) and 10 mg/ml pepstatin A) for 48 h at 4C. The ex-
tracts were centrifuged at 10,000 rpm for 30 min at 4C
and the supernatants were dialyzed for 48 h at 4C against
10 mM sodium acetate, pH 6.0. For analysis of total tissue
hyaluronate, 100 mg cartilage was digested with 1 mgproteinase K in 50 mM Tris/HCl, pH 7.6, containing 1 mM
EDTA, 1 mM iodacetamide and 10 mg/ml pepstatin A by
incubation at 56C overnight, followed by inactivation of
the proteinase K by incubation at 100C for 5 min.ENZYMIC DEGLYCOSYLATION OF PROTEOGLYCANSBefore further analysis by immunoblotting, the cartilage
extracts and conditioned media samples (both dialyzed
against 10 mM sodium acetate, pH 6.0 for 48 h at 4C)
were treated with keratanase II (Seikagaku) and chondroiti-
nase ABC (MP Biomedicals). The samples were incubated
at 37C overnight in the presence of keratanase II at a ﬁnal
concentration of 20 mU/ml. The buffer was then adjusted to
0.1 M Tris/HCl, 0.1 M sodium acetate, pH 7.3, and followed
by treatment with chondroitinase ABC (200 mU/ml) for 4 h
at 37C. Both enzymes were inactivated by incubation of
the samples at 100C for 5 min.SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL
ELECTROPHORESIS (SDS/PAGE) AND IMMUNOBLOTTINGThe tissue and media samples were analyzed on Novex
4e12% gradient NuPAGE BiseTris gels (Invitrogen) and
electroblotted as recommended by the manufacturer using
a Novex transfer apparatus to nitrocellulose membranes
(BioRad). The membranes were then blocked overnight
in 5% skim milk (Carnation Instant Milk Powder) in Tris-
buffered saline containing 0.1% Tween 20. Aggrecan and
its degradation products were detected using rabbit
polyclonal antibodies recognizing the amino terminal G1
region15 and the carboxy terminal G3 region10 of bovine ag-
grecan. The anti-G1 region antibody recognizes all G1 pres-
ent on aggrecan or as a proteolytically generated fragment,
and can distinguish the G1 region generated by aggreca-
nases and MMPs based on their characteristic sizes. The
mouse monoclonal antibody 8A4 (obtained from the Devel-
opmental Studies Hybridoma Bank, University of Iowa,
USA) was used to detect LP16. Bound antibodies were
then visualized by incubation with either anti-rabbit Ig- or
anti-mouse Ig-biotinylated antibody (Amersham), followed
by incubation in the presence of a streptavidinebiotinylated
horseradish peroxidase (HRP) complex (Amersham), en-
hanced chemiluminescence (ECL) Plus Western blotting
detection reagents (Amersham), and exposure to Hyperﬁlm
(Amersham).PREPARATION OF BIOTINYLATED HA BINDING PROTEIN
(HABP)Proteoglycan was extracted from bovine nasal cartilage
using 4 M guanidinium chloride, and proteoglycan aggre-
gates were recovered by cesium chloride density gradient
centrifugation under associative conditions17. The proteo-
glycan aggregates (50 mg) were dissolved at 5 mg/ml in
50 mM TriseHCl, 100 mM NaCl, 1 mM CaCl2, pH 7.5, and
digested with trypsin at 10 mg/mg proteoglycan for 6 h at
37C. Trypsin action was stopped by the addition of soy-
bean trypsin inhibitor to 100 mg/ml. The mini-aggregates
(consisting of the aggrecan G1 domain and LP bound to
HA) present in the digests were puriﬁed by gel ﬁltration
chromatography through Sepharose CL-2B, where they
elute at the void volume. Gel ﬁltration was carried out in
50 mM TriseHCl, 150 mM NaCl, pH 7.5, and fractions
were collected and analyzed for absorbance at 280 nm
and GAG content14. The mini-aggregates (6 mg) were
100 M. Durigova et al.: Proteoglycan aggregate degradationdissolved in 440 ml 100 mM HEPES, pH 7.5, then 60 ml N-
hydroxysulfosuccinimide (1 mg/ml) was added. After 20 min,
500 ml 8 M guanidinium chloride was added to dissociate
the mini-aggregates, and the biotinylated G1 and LP
(HABPs) were isolated by gel ﬁltration chromatography
through Sepharose CL-4B, where they elute in the included
volume. Gel ﬁltration was carried out in 4 M guanidinium
chloride, 100 mM TriseHCl, pH 7.5, and the elution of the
biotinylated HABPs was monitored by absorbance at
280 nm. The identity of the biotinylated HABPs was con-
ﬁrmed by SDS/PAGE and electroblotting, using a streptavi-
din-conjugated detection system. Fractions containing the
HABPs were dialyzed into phosphate buffered saline
(PBS) and stored at 50 mg/ml at 20C.HA ASSAYA modiﬁed version of the competitive binding assay de-
scribed by Goldberg18 was used to measure HA release
into the culture media. HA (from human umbilical cord,
Sigma) was puriﬁed using a modiﬁcation19 of the method of
Cleland and Sherblom20 and used as a standard (ranging
from 200 to 5 ng/well) and to coat (20 mg/well) 96-well plates
(Immulon-2, Nunc). Both standards and samples were ﬁrst
incubated with biotinylated HABP (1 mg/ml) for 4 h at 4C
and then transferred toHA-coated plates and incubatedover-
night at 4C. HABP bound to the HA-coated plates was
detected by incubationwith a streptavidinealkaline phospha-
tase conjugate (Roche) for 1 h at 37C followed by color de-
velopment using a phosphatase substrate (Sigma) and
monitored at 405 nm. To avoid any interference from aggre-
can or other HABPs present in the samples, the culture
media and tissue extracts were reduced and alkylated prior
to further analysis21.ANALYSIS OF HA SIZE DISTRIBUTIONTo determine the size distribution of released HA, the cul-
ture media were analyzed by electrophoresis on agarose
gels22 followed by capillary transfer to a membrane derivat-
ized with a cationic detergent, followed by detection using
biotinylated HABP and ECL reagents (Amersham). The re-
duced and alkylated media and total tissue HA samples
(20 ml) were separated on 0.9% agarose (SeaKem) gels
at 90 V for 1.5 h and transferred to cetylpyridinium chloride
(CPC)-treated nitrocellulose membranes23. Membranes
were then blocked with 5% dried milk in Tris-buffered saline
containing 0.1% Tween 20. Biotinylated HABP was then
used in combination with streptavidinebiotinylated HRP
complex (Amersham) and ECL Plus Western blotting detec-
tion reagents (Amersham) in order to detect the HA.DATA ANALYSISThe GAG and HA release data were analyzed for statis-
tical signiﬁcance using the paired Student’s t test.Fig. 1. GAG release from cartilage cultures in response to cytokine
stimulation. Bovine articular cartilage explants were cultured with
the cytokines IL-1b (upper panel), IL-1a (middle panel), or TNFa
(lower panel) with or without OSM. Results are shown for cytokine
alone (hatched bars), OSM alone (gray bars), both factors (solid
bars) or no factor (open bars). Culture media collected after each
2-day medium change were analyzed for GAG content by the
DMMB dye-binding assay. *P< 0.05.Results
In order to investigate the effects of different combinations
of catabolic cytokines as mediators of GAG release, adult
bovine articular cartilage was maintained in explant culture
for up to 6 days and in the presence of IL-1a, IL-1b, TNFa,
IL-6, IL-17 and OSM and various combinations of these
cytokines. IL-6 and IL-17 alone showed no variation fromcontrol cultures. While IL-1a, IL-1b, TNFa or OSM by them-
selves induced substantial GAG loss from the tissue, in all
cases the most effective and rapid response was obtained
with OSM in combination with either IL-1a, IL-1b, or TNFa
(Fig. 1) all of which resulted in release of an estimated
70e80% of the constituent GAGs by day 4. Maximal release
of GAG occurred 2 days after commencement of cytokine
stimulation with release declining at subsequent days.
Analysis of the mechanisms of the proteolysis of the con-
stituent aggrecan in the tissue was investigated by extract-
ing the cartilage after 6 days in culture with 4 M guanidinium
chloride and analyzing the resulting proteins by immuno-
blotting using an antibody to the G1 region of aggrecan
(Fig. 2, upper panel). As expected for young adult articular
cartilage, where the G1 region is present almost exclusively
Fig. 2. Analysis of aggrecan G1 generation. Samples of cartilage
extracts after 6 days of culture (upper panel) and pooled media col-
lected at days 2, 4 and 6 of culture (lower panel) were treated with
chondroitinase ABC and keratanase II, then analyzed by SDS/
PAGE and immunoblotting using an antibody to the aggrecan G1
domain. Lane 1, control; lane 2, IL-1b; lane 3, IL-1bþ IL-6; lane
4, IL-1bþ IL-17; lane 5, IL-1bþOSM; lane 6, IL-1bþ IL-6þ IL-
17 þOSM; lane 7, OSM; lane 8, TNFa; lane 9, TNFa þOSM.
The migration position of aggrecanase-generated free G1 is indi-
cated on the right. Migration positions of molecular weight stan-
dards are indicated on the left. Results shown in lanes 1e6 and
7e9 represent two different experiments.
Fig. 3. Analysis of LP. Samples of cartilage extracts (upper panel)
and medium pooled from 6 days of culture (lower panel) were
treated with chondroitinase ABC and keratanase II, then analyzed
by SDS/PAGE and immunoblotting using a mouse monoclonal an-
tibody to LP. Lane 1, control; lane 2, IL-1b; lane 3 IL-1bþ IL-6; lane
4, IL-1bþ IL-17; lane 5, IL-1bþOSM; lane 6, IL-1bþ IL-6þ IL-
17 þOSM; lane 7, OSM; lane 8, TNFa; lane 9, TNFa þOSM.
Migration positions of molecular weight standards and LP are indi-
cated. Additional bands seen in the medium samples are due to
non-speciﬁc reaction of the second step antibody with contami-
nants in the BSA used as a carrier for the cytokines in the culture
medium. Results shown in lanes 1e6 and 7e9 represent two
different experiments.
Fig. 4. Release of HA from cartilage explants. Medium samples
were reduced and alkylated and HA content was measured using
a competitive binding assay. Cytokine combinations used are
indicated in the inset. *P< 0.05.
101Osteoarthritis and Cartilage Vol. 16, No. 1as a component of aggrecan, almost no free G1 was ob-
served in the control tissue (lane 1), whereas increased
levels were seen in the tissues cultured in the presence of
cytokines, where proteolytic generation of the free aggrecan
G1 is expected (lanes 2e9). However, it was apparent that
when OSM was used in combination with the other cyto-
kines (lanes 5, 6 and 9) free G1 levels in the tissue were
lower than expected. The extremely high level of GAG re-
lease observed for tissues cultured with the OSM/IL-1a,
and OSM/IL-1b mixtures (Fig. 1) suggested that most of
the constituent aggrecan should have been cleaved. Ac-
cordingly when the culture medium was analyzed high
levels of G1 were detected (Fig. 2, lower panel, lanes 5, 6
and 9), suggesting that OSM modulates production and re-
lease of free G1 from the tissue. The molecular size of the
G1 immunoproduct was consistent with the action of aggre-
canases as was demonstrated previously15 and veriﬁed by
anti-neoepitope antibody analysis. There was no indication
of MMP action with any of the cytokines under study.
Unless the G1 domain had been proteolytically damaged
(for which there was no evidence by immunoblotting) the G1
released from the tissue should be functional and might be
expected to be accompanied by LP and HA. Immunoblot-
ting of extracts and medium of cartilage cultured under
the conditions indicated above showed that LP was re-
tained in the tissue in the case of cartilage cultured with
IL-1b and TNFa alone, but was released into the medium
when these cytokines were used in combination with
OSM (Fig. 3), suggesting that under the conditions whereexcessive GAG release was occurring, the G1 domains
and LP would also be released in association with HA.
Using a competitive binding assay, HA levels in the differ-
ent culture media were determined (Fig. 4). Some HA re-
lease was observed in the control cultures, but the level
of release did not change markedly with time in culture.
No change in HA release was observed in cultures incu-
bated with IL-1b, and there was a tendency for IL-1a to
Fig. 6. Inhibition of hyaluronidase activity. Bovine articular cartilage
explants were cultured alone (open bar), in the presence of IL-
1bþOSM (solid bar), or in the presence of IL-1bþOSMþ apigenin
(100 mM, gray bar). Media from days 2 and 4 of culture were
pooled, reduced and alkylated and analyzed for HA content.
*P< 0.05.
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particular in conjunction with IL-1b or IL-1a, resulted in the
release of increased levels of HA, in agreement with the
proposal that all components of the proteoglycan aggregate
were being lost into the culture medium. The size of the HA
released into the medium in each case was assessed by
agarose gel electrophoresis (Fig. 5). The total tissue con-
tent of this molecule, isolated by proteinase K digestion of
the uncultured tissue, showed a somewhat heterogenous
but high molecular weight distribution on the gel (lane 7).
In contrast, the hyaluronate released in the presence of
the OSM/IL-1b, and OSM/IL-1a mixtures (lanes 4 and 6) in-
dicated a much lower size, suggesting that it had under-
gone cleavage.
To determine whether HA release was mediated by hyal-
uronidase action, cartilage cultures were carried out in the
presence of the hyaluronidase inhibitor, apigenin. HA release
was diminished in the presence of 100 mM apigenin (Fig. 6),
a concentration previously reported not to affect cell viabil-
ity24. Thus it would appear that one or more chondrocyte hy-
aluronidasesareparticipating in cartilagematrix degradation.
The production of high levels of G1 domain in the tissues
cultured in the presence of the OSM/cytokine mixtures sug-
gested that the aggrecan was undergoing substantial prote-
olysis. Immunoblotting using an antiserum speciﬁc for the
C-terminal G3 aggrecan domain (Fig. 7) demonstrated
that while intact aggrecan was detectable in the control tis-
sue (lane 1), no G3-containing material remained in the car-
tilage cultured in the presence of cytokines. However, in the
culture medium a well-established pattern of G3-containing
fragments in the 100e200 kDa range was observed repre-
senting the products of aggrecanase cleavage in the CS2
domain10. This indicates that extensive aggrecanase activ-
ity was generated in the tissue in the presence of the cyto-
kines. Of special signiﬁcance was the observation of
a novel low molecular weight (50 kDa) G3-containing
band in the medium of cartilage cultured in the presence
of OSM (lanes 5, 6, 7 and 9).Discussion
Using bovine articular cartilage we have demonstrated
that OSM, particularly in combination with the catabolicFig. 5. Analysis of HA size. Medium samples taken at day 4 of cul-
ture were analyzed by agarose gel electrophoresis, followed by
capillary blotting to CPC-treated nitrocellulose membranes and
visualization using a biotinylated HABP. Lane 1, control; lane 2,
OSM; lane 3, IL-1b; lane 4, IL-1bþOSM; lane 5, IL-1a; lane 6,
IL-1aþOSM; lane 7, cartilage digest.
Fig. 7. Analysis of aggrecan G3-containing components. Samples
of cartilage extracts (upper panel) and medium pooled from 6
days of culture (lower panel) were treated with chondroitinase
ABC and keratanase II, then analyzed by SDS/PAGE and immuno-
blotting using an antibody to the aggrecan G3 domain. Lane 1, con-
trol; lane 2, IL-1b; lane 3, IL-1bþ IL-6; lane 4, IL-1bþ IL-17; lane 5,
IL-1bþOSM; lane 6, IL-1bþ IL-6þ IL-17þOSM; lane 7, OSM;
lane 8, TNFa; lane 9, TNFaþOSM. Positions of molecular weight
standards are indicated on the left and the position of aggrecanase-
generated G3-containing components due to CS2 cleavage is indi-
cated on the right. The additional band (w81 kDa) seen in lanes
7e9 is due to non-speciﬁc reaction of the second step antibody
with contaminants in some BSA preparations used as a carrier
for the cytokines in the culture medium. Results shown in lanes
1e6 and 7e9 represent two different experiments.
103Osteoarthritis and Cartilage Vol. 16, No. 1cytokines IL-1a, IL-1b or TNFa, has the ability to stimulate
not only aggrecan degradation, but also aggrecan G1, LP
and HA release. It is well accepted that catabolic cytokines
mediate the release of aggrecan from cartilage in vitro and
that OSM is also an effective agent in this regard, also me-
diating the release of collagen when extended culture times
are studied25. The catabolic effect of these cytokines is en-
hanced by their ability to down regulate aggrecan synthesis
and prevent replacement of aggrecan loss from the matrix
by catabolism26e28. Thus with increased culture time, aggre-
can loss from the matrix declines. The present work clearly
demonstrates that in addition to the induction of aggreca-
nase activity in cartilage, OSM also greatly enhances the
ability of the tissue to degrade HA. Two possible mecha-
nisms for HA degradation can be considered, cleavage
with a glycohydrolase (hyaluronidase) or the action of reac-
tive oxygen species (ROS). Evidence against the role of
ROS in cytokine-mediated GAG release has already been
presented by others based on the use of radical
scavengers29.
Release of HA from cartilage has been demonstrated
previously21,29 and a role for hyaluronidases has been pro-
posed. Recently, data from cloning studies and various ge-
nome projects have demonstrated the existence of a family
of hyaluronidases present in all mammalian species30 and
some of the family members have been detected in cartila-
ge31e33. However, the nature of the activities mediating HA
cleavage in the present study remains unknown. Previously
hyaluronidases have been believed to function only at very
acid pH values making their extracellular role unlikely. This
view has changed recently with the realization that several
forms of the enzyme are fully active at neutral pH32,34 and
are not sequestered in the lysosome but are located at
the cell surface. Thus the action of one or more cell surface
localized hyaluronidases appears likely in the current study.
This hypothesis is supported by culture experiments using
the general hyaluronidase inhibitor apigenin32, which dem-
onstrated a dramatic reduction in HA release from OSM-
stimulated cartilage. It should be noted that ﬂavonoids
such as apigenin can have several effects on cellular
metabolism35. However, analysis using the live/dead cell
assay showed that cell death is not a factor contributing
to HA release under the conditions used (data not shown).
The results presented in this work also demonstrate that
release of HA is dependent on high levels of concomitant
proteolysis as monitored by aggrecan degradation. It is,
however, not known whether different cytokines result in dif-
ferent degrees of hyaluronidase stimulation or in the upre-
gulation of different hyaluronidases. Even if limited
hyaluronate degradation occurs in situ it is possible that
its loss from the tissue will not occur unless aggrecan deg-
radation takes place simultaneously to reduce the size of
the remaining proteoglycan aggregate fragments or permit
access of the hyaluronidase to the hyaluronate ﬁlament.
Prior studies to elucidate the contribution of hyaluronidases
vs proteases in mediating HA release have been
contradictory29,36.
Another major ﬁnding from this study is the demonstration
that, under high levels of catabolic stimulation due to the
action of OSM, an aggrecan G3 fragment is released from
cartilage. To date aggrecanases have been shown to
cleave aggrecan at a series of well-characterized sites, all
of which occur directly following a glutamic acid residue9.
Several in vitro studies demonstrate that substrate cleavage
is limited to these sites10,37, suggesting that OSM may be
inducing the production of an additional proteolytic activity.
However, aggrecanases have been shown to cleave othersubstrates at non-canonical sites38,39. More importantly it
has been demonstrated that aggrecanases undergo C-ter-
minal auto-processing40, and that substrate speciﬁcity is al-
tered depending on the degree of processing that has taken
place41,42. Thus it is likely that high levels of aggrecanase
production will result in extensive intermolecular proteolysis
of aggrecanases with the generation of additional aggrecan
cleavage products. Interestingly, a G3 fragment of similar
size has been identiﬁed under certain conditions of in vitro
aggrecan degradation by aggrecanases (unpublished ob-
servations), and in bovine fetal cartilage cultured in the
presence of IL-1 or retinoic acid, but in the absence of ex-
ogenous OSM43. Such cultures have also been reported
to give HA release in the absence of OSM21, in contrast
to more mature cartilage. This could be due to different pro-
teolytic processing of the aggrecanases with cartilage age,
or to the endogenous production of OSM by some cartilage
under cytokine stimulation.
Demonstration that proteoglycan loss, characteristic of
arthritic cartilage, is not due solely to the action of proteases
but that HA degradation may also be involved provides an
additional target for the reduction of proteoglycan loss in
the arthritic joint. At present it is not clear whether OSM ac-
tion is conﬁned to inﬂammatory forms of arthritis or could
also participate in osteoarthritis. However, it is certainly fea-
sible that OSM could be released into the synovial ﬂuid in
osteoarthritic joints when synovial inﬂammation is present.Acknowledgements
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